Cyclin E as a prognostic and predictive marker in breast cancer

Seminars in Cancer Biology

Volumn 15, Issue 4, 2005, Pages 319-326

  Hunt, Kelly K ^a   Keyomarsi, Khandan ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Cell cycle; Cyclin E; Low molecular weight isoforms; Predictive factors; Prognostic factors

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ELASTASE INHIBITOR; FLAVOPIRIDOL; FLUOROURACIL; METHOTREXATE; MOLECULAR MARKER; PACLITAXEL; ROSCOVITINE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; DNA MICROARRAY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STATISTICAL SIGNIFICANCE;

BREAST NEOPLASMS; CYCLIN E; FEMALE; HUMANS; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 23044444181     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2005.04.007     Document Type: Review

References (86)

1. A. Koff, F. Cross, A. Fisher, J. Schumacher, K. Leguellec, and M. Philippe Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family Cell 66 1991 1217 1228
2. D.J. Lew, V. Dulic, and S.I. Reed Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast Cell 66 1991 1197 1206
3. A. Koff, A. Giordano, D. Desia, K. Yamashita, J.W. Harper, and S.J. Elledge Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle Science 257 1992 1689 1694
4. M. Ohtsubo, A.M. Theodoras, J. Schumacher, J.M. Roberts, and M. Pagano Human cyclin E, a nuclear protein essential for the G1-to-S phase transition Mol Cell Biol 15 1995 2612 2624
5. M. Ohtsubo, and J.M. Roberts Cyclin-dependent regulation of G1 in mammalian fibroblasts Science 259 1993 1908 1912
6. K. Keyomarsi, and A. Pardee Redundant cyclin overexpression and gene amplification in breast cancer cells Proc Natl Acad Sci USA 90 1993 1112 1116
7. M.F. Buckley, K.J.E. Sweeney, J.A. Hamilton, R.L. Sini, D.L. Manning, and R.I. Nicholson Expression and amplification of cyclin genes in human breast cancer Oncogene 8 1993 2127 2133
8. A. Sgambato, Y. Doki, I. Schieren, and I.B. Weinstein Effects of cyclin E overexpression on cell growth and response to transforming growth factor β depend on cell context and p27kip1 expression Cell Growth Differ 8 1997 393 405
9. K. Keyomarsi, D. Conte Jr., W. Toyofuku, and M.P. Fox Deregulation of cyclin E in breast cancer Oncogene 11 1995 941 950
10. D.M. Bortner, and M.P. Rosenberg Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E Mol Cell Biol 17 1997 453 459
11. C.H. Spruck, K.A. Won, and S.I. Reed Deregulated cyclin E induces chromosome instability Nature 401 1999 297 300
12. K. Keyomarsi, N. O'Leary, G. Molnar, E. Lees, H.J. Fingert, and A.B. Pardee Cyclin E, a potential prognostic marker for breast cancer Cancer Res 54 1994 380 385
13. K. Keyomarsi, and T.W. Herliczek The role of cyclin E in cell proliferation, development and cancer Prog Cell Cycle Res 3 1997 171 191
14. N.H. Nielsen, C. Arnerlov, S.O. Emdin, and G. Landberg Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status Br J Cancer 74 1996 874 880
15. Q.-S. Wang, C.L.K. Sabourin, H. Wang, and G. Stoner Overexpression of cyclin D1 and cyclin E in N-nitrosomethylbenzylamine-induced rate exophageal tumorigenesis Cacinogenesis 17 1996 1583 1588
16. R. Scuderi, K.A. Palucka, K. Pokrovskaja, M. Bjorkholm, K.G. Wiman, and P. Pisa Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage Blood 8 1996 3360 3367
17. K. Keyomarsi, S.L. Tucker, T.A. Buchholz, M. Callister, Y. Ding, and G.N. Hortobagyi Cyclin E and survival in patients with breast cancer N Engl J Med 347 2002 1566 1575
18. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
19. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, and D.E. Keith Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
20. N.E. Hynes Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy Semin Cancer Biol 4 1993 19 26
21. V.R. Chazin, M. Kaleko, A.D. Miller, and D.J. Slamon Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor Oncogene 7 1992 1859 1866
22. C.C. Benz, G.K. Scott, J.C. Sarup, R.M. Johnson, D. Tripathy, and E. Coronado Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu Breast Cancer Res Treat 24 1993 85 95
23. G.D. Lewis, I. Figari, B. Fendly, W.L. Wong, P. Carter, and C. Gorman Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies Cancer Immunol Immunother 37 1993 255 263
24. M.F. Press, L. Bernstein, P.A. Thomas, L.F. Meisner, J.Y. Zhou, and Y. Ma HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 1997 2894 2904
25. P.M. Ravdin, and G.C. Chamness The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review Gene 159 1995 19 27
26. C.M. Perou, T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, and C.A. Rees Molecular portraits of human breast tumours Nature 406 2000 747 752
27. T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, and H. Johnsen Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 2001 10869 10874
28. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, and M. Cronin A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826
29. F.J. Esteva, A.A. Sahin, K. Coombes, J. Baker, M. Cronin, and M.G. Walker Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - MD Anderson Cancer Validation Study Breast Cancer Res Treat 82 2003 S11
30. S. Paik, J. Bryant, E. Tan-Chiu, G. Yothers, C. Park, and D.L. Wickerham HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 J Natl Cancer Inst 92 2000 1991 1998
31. H.B. Muss, A.D. Thor, D.A. Berry, T. Kute, E.T. Liu, and F. Koerner c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer N Eng J Med 330 1994 1260 1266
32. A.D. Thor, D.A. Berry, D.R. Budman, H.B. Muss, T. Kute, and I.C. Henderson erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J Natl Cancer Inst 90 1998 1346 1360
33. D. Allred, G. Clark, R. Molina, A. Tandon, S. Schnitt, and K. Gilchrist Overexpression of Her-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer Hum Pathol 23 1992 974 979
34. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, and L. Dantis Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 1996 737 744
35. M.A. Cobleigh, C.L. Vogel, D. Tripathy, N.J. Robert, S. Scholl, and L. Fehrenbacher Efficacy and safety of Herceptin as a single agent in 222 women with Her-2 overexpression who relapsed following chemotherapy for metastatic breast cancer Proc Am Soc Clin Oncol 17 1998 97a
36. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
37. Y. Nagata, K.H. Lan, X. Zhou, M. Tan, F.J. Esteva, and A.A. Sahin PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127
38. P.C. Clahsen, C.J. van de Velde, C. Duval, C. Pallud, A.M. Mandard, and A. Delobelle-Deroide p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer J Clin Oncol 16 1998 470 479
39. M. Mottolese, M. Benevolo, G. Del Monte, S. Buglioni, P. Papaldo, and C. Nistico Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy J Cancer Res Clin Oncol 126 2000 722 729
40. P.N. Munster, and L. Norton Predictive factor for the response to adjuvant therapy with emphasis in breast cancer Breast Cancer Res 3 2001 361 364
41. J. Sjostrom Predictive factors for response to chemotherapy in advanced breast cancer Acta Oncol 41 2002 334 345
42. D.A. Berry, H.B. Muss, A.D. Thor, L. Dressler, E.T. Liu, and G. Broadwater HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer J Clin Oncol 18 2000 3471 3479
43. A.S. Knoop, S.M. Bentzen, M.M. Nielsen, B.B. Rasmussen, and C. Rose Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients J Clin Oncol 19 2001 3376 3384
44. M. Stendahl, A. Kronblad, L. Ryden, S. Emdin, N.O. Bengtsson, and G. Landberg Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients Br J Cancer 90 2004 1942 1948
45. P. Manders, L.V. Beex, V.C. Tjan-Heijnen, P.N. Span, and C.G. Sweep Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma Cancer 98 2003 2125 2132
46. M. Ayers, W.F. Symmans, J. Stec, A.I. Damokosh, E. Clark, and K. Hess Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J Clin Oncol 22 2004 2284 2293
47. M.P. Jansen, J.A. Foekens, I.L. van Staveren, M.M. Dirkzwager-Kiel, K. Ritstier, and M.P. Look Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling J Clin Oncol 23 2005 732 740
48. M.J. van de Vijver, Y.D. He, L.J. van't Veer, H. Dai, A.A. Hart, and D.W. Voskuil A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009
49. S. Akli, and K. Keyomarsi Cyclin e and its low molecular weight forms in human cancer and as targets for cancer therapy Cancer Biol Ther 2 2003 S38 S47
50. Akli S, Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res 2004;6(5):188-91.
51. V. Dulic, L. Drullinger, E. Lees, S. Reed, and G. Stein Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-cdk2 and cyclin D1-cdk2 complexes Proc Natl Acad Sci USA 90 1993 11034 11038
52. A. Sgambato, E.K. Han, P. Zhou, I. Schieren, and I.B. Weinstein Overexpression of cyclin E in the HC11 mouse mammary epithelial cell line is associated with growth inhibition and increased expression of p27(Kip1) Cancer Res 56 1996 1389 1399
53. K.R. Johnson, L. Wang, M.C. Miller III, M.C. Willingham, and W. Fan 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells Clin Cancer Res 3 1997 1739 1745
54. M.L. Smith, and Y.R. Seo Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations Anticancer Res 20 2000 2537 2539
55. P.N. Span, V.C. Tjan-Heijnen, P. Manders, L.V. Beex, and C.G. Sweep Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer Oncogene 22 2003 4898 4904
56. M.D. Planas-Silva, and R.A. Weinberg Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution Mol Cell Biol 17 1997 4059 4069
57. J.S. Carroll, O.W. Prall, E.A. Musgrove, and R.L. Sutherland A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence J Biol Chem 275 2000 38221 38229
58. O.W.J. Prall, B. Sarcevic, E.A. Musgrove, C.K.W. Watts, and R.L. Sutherland Estrogen-induced activation of cdk4 and cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2 J Biol Chem 272 1997 10882 10894
59. G. Kaur, M. Stetler-Stevenson, S. Sebers, P. Worland, H. Sedlacek, and C. Myers Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275 J Natl Cancer Inst 84 1992 1736 1740
60. P.J. Worland, G. Kaur, M. Stetler-Stevenson, S. Sebers, O. Sartor, and E.A. Sausville Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity Biochem Pharmacol 46 1993 1831 1840
61. B.A. Carlson, M.M. Dubay, E.A. Sausville, L. Brizuela, and P.J. Worland Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells Cancer Res 56 1996 2973 2978
62. T. Tamaoki Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors Methods Enzymol 201 1991 340 347
63. L. Meijer, A. Borgne, O. Mulner, J.P.J. Chong, J.J. Blow, and N. Inagaki Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases, cdc2, cdk2, and cdk5 Eur J Biochem 243 1997 527 536
64. K.S. Kim, S.D. Kimball, R.N. Misra, D.B. Rawlins, J.T. Hunt, and H.Y. Xiao Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities J Med Chem 45 2002 3905 3927
65. K.S. Kim, J.S. Sack, J.S. Tokarski, L. Qian, S.T. Chao, and L. Leith Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects J Med Chem 43 2000 4126 4134
66. A.R. Tan, X. Yang, A. Berman, S. Zhai, A. Sparreboom, and A.L. Parr Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer Clin Cancer Res 10 2004 5038 5047
67. G.K. Schwartz, E. O'Reilly, D. Ilson, L. Saltz, S. Sharma, and W. Tong Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors J Clin Oncol 20 2002 2157 2170
68. G.K. Schwartz, D. Ilson, L. Saltz, E. O'Reilly, W. Tong, and P. Maslak Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma J Clin Oncol 19 2001 1985 1992
69. Jones SF, Burris HA, Kies M, Willcutt N, Degan P, Bai S, et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. Proc Am Soc Clin Oncol 2003;22:199 [abstract 799].
70. G.I. Shapiro, J.G. Supko, A. Patterson, C. Lynch, J. Lucca, and P.F. Zacarola A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer Clin Cancer Res 7 2001 1590 1599
71. V. Laurence, S. Faivre, K. Vera, J.-Y. Pierga, C. Delbaldo, and M. Bekradda Preliminary results of an ongoing phase 1 and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies Eur J Cancer 38 2002 S49
72. Pierga J-Y, Faivre S, Vera K, Laurence V, Delbaldo C, Bekradda M, et al. A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2003;22:210 [abstract 840].
73. Mani S, McDaid H, Goel S, Goldberg GA, Sparano J, Cohen M, et al. Expanded evaluation of BMS-247550 (BMS) using a 1 hr infusion at the recommended phase II dose (RPTD). Proc Am Soc Clin Oncol 2003;22:248 [abstract 995].
74. W.M. Stadler, N.J. Vogelzang, R. Amato, J. Sosman, D. Taber, and D. Liebowitz Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study J Clin Oncol 18 2000 371 375
75. Patel B, El-Rayes BF, Gadgeel SM, Lorusso P, Philip PA. A phase I study of flavopiridol and docetaxel. Proc Am Soc Clin Oncol 2003;22:233 [abstract 932].
76. J. Gries, B. Kasimis, Schwarzenberger, G.I. Shapiro, P. Fidias, and L. Rodrigues Phase I study of flavopiridol (HMR1275) in combination with paclitaxel and carboplatin in non-small cell lung cancer (NSCLC) patients Eur J Cancer 38 2001 S49
77. Bible KC, Lensing JL, Nelson SA, Atherton PJ, Sloan JA, Erlichman C. A phase I trial of flavopiridol combined with 5-fluorouracil (5-FU) and leucovorin (CF) in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003;22:218 [abstract 872].
78. Mull B, Keyomarsi K. Role of phosphorylation in the appearance of lower molecular weight forms of cyclin E. Proc Am Assoc Cancer Res 2004;45:599 [abstract 2592].
79. D.C. Porter, N. Zhang, C. Danes, M.J. McGahren, R.M. Harwell, and S. Faruki Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms Mol Cell Biol 21 2001 6254 6269
80. J.I. Yamahista, M. Ogawa, S. Ikel, H. Omachi, S.I. Yamshita, and T. Saishoji Production of immunoreactive polymorphonuclear leucocyte elastase in the progression of human breast cancer Br J Cancer 69 1994 72 76
81. J.A. Foekens, C. Ries, M.P. Look, C. Gippner-Steppert, J.G. Klijn, and M. Jochum Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease Br J Cancer 88 2003 1084 1090
82. J.A. Foekens, C. Ries, M.P. Look, C. Gippner-Steppert, J.G. Klijn, and M. Jochum The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer Cancer Res 63 2003 337 341
83. P.A. Henriksen, M. Hitt, Z. Xing, J. Wang, C. Haslett, and R.A. Riemersma Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli J Immunol 172 2004 4535 4544
84. G.M. Tremblay, E. Vachon, C. Larouche, and Y. Bourbonnais Inhibition of human neutrophil elastase-induced acute lung injury in hamsters by recombinant human pre-elafin (trappin-2) Chest 121 2002 582 588
85. Liu Y, Keyomarsi K, Lu X, Swisher SG, Hunt KK. Induction of apoptosis in human breast cancer cells following adenovirus-mediated Elafin gene expression in vitro. Proc Am Assoc Cancer Res 2005;46 [abstract 5320].
86. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, and E. Ward Cancer statistics, 2004 Cancer J Clin 54 2004 8 29